Repurposing High-Throughput Image Assays Enables Biological Activity Prediction for Drug Discovery.

Journal: Cell chemical biology
Published Date:

Abstract

In both academia and the pharmaceutical industry, large-scale assays for drug discovery are expensive and often impractical, particularly for the increasingly important physiologically relevant model systems that require primary cells, organoids, whole organisms, or expensive or rare reagents. We hypothesized that data from a single high-throughput imaging assay can be repurposed to predict the biological activity of compounds in other assays, even those targeting alternate pathways or biological processes. Indeed, quantitative information extracted from a three-channel microscopy-based screen for glucocorticoid receptor translocation was able to predict assay-specific biological activity in two ongoing drug discovery projects. In these projects, repurposing increased hit rates by 50- to 250-fold over that of the initial project assays while increasing the chemical structure diversity of the hits. Our results suggest that data from high-content screens are a rich source of information that can be used to predict and replace customized biological assays.

Authors

  • Jaak Simm
    ESAT-STADIUS, KU Leuven, Kasteelpark Arenberg 10, 3001 Leuven, Belgium.
  • Günter Klambauer
    ELLIS Unit Linz and LIT AI Lab, Institute for Machine Learning, Johannes Kepler University Linz, A-4040 Linz, Austria.
  • Adam Arany
    ESAT-STADIUS, KU Leuven, Kasteelpark Arenberg 10, 3001 Leuven, Belgium.
  • Marvin Steijaert
    Open Analytics NV, Jupiterstraat 20, 2600 Antwerp, Belgium.
  • Jörg Kurt Wegner
    Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.
  • Emmanuel Gustin
    Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.
  • Vladimir Chupakhin
    Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.
  • Yolanda T Chong
    The Donnelly Centre, University of Toronto, Toronto, ON M5S3E1, Canada.
  • Jorge Vialard
    Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.
  • Peter Buijnsters
    Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.
  • Ingrid Velter
    Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.
  • Alexander Vapirev
    Facilities for Research, KU Leuven, Willem de Croylaan 52c, Box 5580, 3001 Leuven, Belgium.
  • Shantanu Singh
    Imaging Platform, Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, MA 02142, USA.
  • Anne E Carpenter
    The Broad Institute of MIT and Harvard, 415 Main Street, Cambridge, MA 02142, United States. Electronic address: anne@broadinstitute.org.
  • Roel Wuyts
    ExaScience Life Lab, IMEC, Kapeldreef 75, 3001 Leuven, Belgium.
  • Sepp Hochreiter
    Institute for Machine Learning Johannes Kepler University Linz Austria.
  • Yves Moreau
    ESAT-STADIUS, KU Leuven, Kasteelpark Arenberg 10, 3001 Leuven, Belgium.
  • Hugo Ceulemans
    Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium. Electronic address: hceulema@its.jnj.com.